Houston innovator raises pre-seed funding for health care staffing platform

just closed

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. Photo courtesy of Lokum

A Houston health care innovator is celebrating an oversubscribed round of pre-seed funding to improve on her startup's unique staffing platform.

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. The new platform, which cuts out the middleman and lowers staffing costs, raised $700,000 in pre-seed funding that will go toward further development of the technology.

"Healthcare organizations spend $26 billion annually to support a crippling dependence on third-party agencies for connecting with clinical staff," Ademuyewo says in a news release. "Technological solutions that are pointed precisely to streamline and strengthen the relationships between highly specialized clinicians and their future employers are vital to alleviating this detrimental dependance, and central to our mission.

"I'm incredibly proud to have earned the trust of my colleagues, investors, team, and mentors in solving this complex problem."

Ademuyewo raised the round with support from local investors, including Aileen Allen, an adviser and investor associated with the Houston Angel Network, Mercury, and The Artemis Fund; and Matt Miller, former Liongard product executive, as well as from Houston-based VC firm South Loop Ventures. Techstars and JP Morgan also contributed to the round.

"Lokum has found a way to disrupt an organically inefficient and expensive market with an elegant solution that doesn't just save hospitals time and money, but also increases the pool of specialty providers in a market that is consistently strapped for such expertise," Jerry Varnado, venture partner at South Loop Ventures, adds. "This is what disruption in healthcare looks like — scalable commercial solutions that contribute towards better patient care, and we're happy to be part of Lokum's journey."

Ademuyewo has the idea to start Lokum after her experience as an independent contract nurse anesthetist amid the height of the pandemic as she witnessed third-party recruitment agencies take advantage of medical professionals like herself.

Now, the platform's early pilot, which focuses on clinicians in anesthesiology, has served clients across nearly 200 hospitals and surgery centers in 20 states. Ademuyewo also participated in 2024’s cohort for the Google for Startups Accelerator Program-North America, where she spent 10 weeks developing and building her company and platform.

The Texas Medical Center has named its second cohort for its United Kingdom-focused health tech accelerator. Photo via TMC

16 digital health, medical device companies selected for UK, TMC accelerator

coming to Hou

For the second time, an accelerator backed by the United Kingdom and hosted by Texas Medical Center Innovation has named 16 companies to its new cohort.

In partnership with Innovate UK, TMC named the new cohort companies in an announcement this week. The companies are divided into two categories — digital health and medical device — and cover a wide range of specialties, from diagnostics and AI monitoring to non-surgical management and more.

The accelerator launched last year with its inaugural cohort with the mission of helping companies make their United States expansion by way of the TMC.

"The first cohort of startups in our accelerator program experienced TMC's capabilities in developing and advancing solutions through cross-collaboration with top minds in clinical care, commercialization and innovation," Devin Dunn, head of the Accelerator for Health Tech at TMC, says in a news release. "We are excited to continue our partnership with Innovate UK and welcome this second cohort to continue our efforts advancing life sciences technologies across the globe."

This year's program begins June 4 and will run through November. According to the TMC, last year's cohort had significant success tapping into the health tech ecosystem in Houston, including engaging with investors, setting up a go-to-market strategy, and making inaugural U.S.-based hires.

“Our Global Incubator Programme selects driven and ambitious innovators looking to scale their technologies globally," adds Jon Hazell, partnership manager for the North America and Global Incubator at Innovate UK. "We are excited for our second cohort of startups to join the programme, supported by the Texas Medical Center accelerator, where world-class mentors and programming will help our entrepreneurs understand and meet the requirements of different markets, and build the necessary partnerships, collaborations, and networks, facilitating their entry into global markets."

The selected medical device companies — and their technologies, as described by the TMC — include:

Cytecom – infectious diagnostic test, powered by cutting-edge optical electrophysiology, detects resistant bacteria in just 45 seconds, enabling doctors to prescribe targeted antibiotics in minutes instead of days
Heartfelt Technologies Ltd – the future of heart failure telemonitoring an automatic, AI supported, non-contact telemonitoring solution for heart failure patients
Neurovalens Ltd – creates wearable neurostimulaton devices that treat a range of conditions in an entirely non-invasive and drug-free way
Oxford Medical Products Limited – a proprietary hydrogel pill that acts as a non-surgical, non-pharmacological obesity treatment that will redefine the obesity treatment market
Phenutest – a rapid point-of-care diagnostic test for urinary tract infection, that confirms infection and appropriate antimicrobial to prescribe within 60 minutes
Plexaa – world's first fully wearable, sensor controlled, bra insert that can deliver safe supraphysiological preconditioning to the breast skin the night before surgery at home
SolasCure Limited – a wound Gel that acts as a single, effective and easy-to-use solution to overcome the challenges to transform chronic wound care
Trueinvivo Limited – a proprietary dosimetry (radiation measurement) system to ensure the precision and accuracy of cancer radiotherapy

The selected digital health companies — and their technologies, as described by the TMC — include:

Axon Diagnostics – offers a suite of solutions to support the needs of modern day diagnostic imaging services, supporting happier lives for clinicians and helping deliver better diagnostic care for all
Kheiron Medical Technologies – regarded as a world leader in the development of AI-enabled cancer diagnostics and monitoring
KiActiv – a technology-enabled digital health model for behaviour change and self-care that rethinks exercise and makes everyday movement an effective personalized medicine for better clinical outcomes
Memory Lane Games – turns memories into games, offering care providers a simple, fun dementia engagement app designed to trigger positive memories and improve socialisation with caregivers and people living with dementia
NeuroVirt Limited – combines immersive VR, AI and computer vision to gamify rehabilitation and quantify patient impairment and improvement
Newton’s Tree – enables healthcare providers to procure, integrate, and monitor third party AI products as part of routine care pathways through its enterprise AI platform
SERG Technologies – uses patented sensor technology and artificial intelligence to transform disease management into a continuous, data driven, and patient specific approach for people with Parkinson’s
Thymia – leverages speech, video, and behavioral analytics gathered via specially designed video games to diagnose conditions like depression, anxiety, and ADHD, alongside critical symptoms like fatigue, mood fluctuations, and memory issues, creating novel mental health biomarkers

The partnership between the U.K. and TMC began in 2018 as a biobridge between the two entities. TMC has expanded into new biobridges with other countries — most recently with The Netherlands — and also has a Danish accelerator that's also running its second cohort this summer.

After growing in Chicago and raising funding, Partum Health selected Houston to expand its femtech platform. Photo via Getty Image

Growing femtech company chooses Houston for first out-of-state expansion

moving in

A startup dedicated to comprehensive pregnancy, birth and postpartum care has expanded from its Chicago birthplace to Houston.

Last summer, Partum Health raised $3.1 million in seed funding, which makes it possible for the company to begin a nationwide expansion. That begins in Space City.

“We looked at states where there is work to do on outcomes for maternal health. Texas rose to the top and Houston, in many ways is fairly close to Chicago, our home city. The really thriving healthcare ecosystem attracted us as well,” CEO and Co-Founder Meghan Doyle tells InnovationMap.

As a mom of a seven-year-old and a nine-year-old herself, Doyle says that she experienced the gap firsthand in what’s available to women beyond what her obstetrician or midwife does.

“You had to work really hard to cobble together the care you needed. It was a matter of putting together my personal experiences of realizing it’s not just me, it’s systematic,” says Doyle. “I couldn’t get that problem out of my head.”

Neither could her co-founder and head of operations, Matt Rogers, a father of twins whose family had to navigate the NICU and life-threatening complications. They started working together on the business in earnest during the COVID shutdown and debuted Partum Health at the beginning of 2021.

Partum has begun partnering with obstetricians and midwives to help select complementary care that includes lactation support, pelvic floor physical therapy, mental health services, nutrition counseling and doula care. What’s unique about the plan is that, from aiding in behavioral health problems to addressing nutritional issues, the user’s team is distributed around the Houston area and are fully virtual. Physical therapy and other services that must be done in-person may take place either in-home or at third-party locations.

“We’re still in the process of credentialing with insurance companies,” says Doyle.

In Illinois, Partum is already working with BlueCross BlueShield, United Healthcare, Aetna and Cigna for clinical care, so Doyle says she is confident that those companies will soon follow suit in Texas.

While hiring a team in Houston that includes a client care lead, Doyle says that Partum is simultaneously providing services and getting to know the market better. They’re also building more bundled models of care to better assist users in their new landscape.

Doyle and Partum Healthcare participated in the Ignite Healthcare Network’s 2023 program, which concluded last week with a pitch competition. Ignite helps female healthcare founders to connect with mentors and other industry experts that will help them navigate the health tech ecosystem. Doyle was one of nine finalists, but did not place in the top three. But she says the program has helped prepare her for success nonetheless.

“In our world, you’re always pitching,” she admits.

The next steps for Partum include a 2024 rife with expansion. Because building relationships with insurance happens on a state-by-state basis, the company will be able to help women around Texas soon after the company is comfortably established in Houston. The Dallas-Fort Worth area will likely be first, followed by Austin and San Antonio.

“We know there’s a huge gap in access to care that may mean evolving a little bit and reaching out across the state,” Doyle says.

Last month, the Texas Health and Human Services Commission reported that 90 percent of the state’s pregnancy-related deaths are preventable. With access to care like what Partum provides, those complications could become a thing of the past.

The Texas Medical Center Innovation Factory has named the 16 companies making up the inaugural cohort in the Innovate UK Global Incubator Programme. Photo via tmc.edu

TMC names inaugural cohort for unique accelerator with UK

coming to HOU

Sixteen digital health and medical device startups founded in the United Kingdom have been selected for a customized accelerator at the Texas Medical Center's Innovation Factory.

In partnership with Innovate UK, TMCi created the Innovate UK Global Incubator Programme, a new accelerator that supports UK businesses as they build their United States go-to-market plan. The program builds the BioBridge relationship between TMC and the UK that was originally established five years ago.

“The TMC UK BioBridge program was launched with the UK Department for Business and Trade in 2018 to serve as a gateway for advancing life sciences and foster innovation and research between our two countries," says Ashley McPhail, chief external affairs and administration officer for TMC, in a news release. "We saw an opportunity to work with Innovate UK to develop a larger program with the UK after the success of the 11 companies that previously participated in our health tech accelerator."

The 16 companies will participate in the program from June to November. The cohort is expected to arrive in Houston on June 5 and have access to TMCi's facilities, network of mentors and potential clients, funding, potential customers, and curated programing — all while being a unique entry point into the US. The new offering joins three other globally recognized curriculums: Biodesign, Accelerator for Cancer Therapeutics, and Health Tech.

“TMCi nurtures long-term growth, development, and competitiveness to increase startups chances of success and global expansion," says Emily Reiser, associate director of TMC Innovation. "By bringing their novel technologies and exposing them to a curated selection of TMC’s expert network, startups receive support and evaluation to build, scale, and expand in the US market."

Two of the cohort's specialties include cardiovascular and oncology — two of TMC's strongest areas of expertise — with solutions ranging from surgical devices to AI-enabled risk stratification and hospital efficiency.

Innovate UK is the country's national innovation agency dedicated to supporting business-led innovation in all sectors.

“The United Kingdom is fully committed to improving global healthcare through scientific collaboration," says His Majesty’s Consul General in Texas Richard Hyde in the release. "Through the expansion of the TMC UK BioBridge and in partnership with Innovate UK, this programme will help to expose the brightest and best British companies to the world’s largest medical city. Our companies will collaborate and grow as they work to develop cutting edge technology. The partnership between the UK Government and TMC demonstrates that international collaboration can drive both economic growth and improvement to quality of life.”

The 16 companies making up the inaugural cohort are as follows, according to TMC.

AINOSTICS aims to revolutionize the treatment and prevention of neurological conditions, such as dementia, by developing innovative AI-enabled solutions that draw novel insights from routinely acquired non-invasive medical scans to deliver accurate diagnosis and outcome prediction, and in turn facilitate personalized care and timely access to disease-modifying treatments for patients.
Alvie is a blended human plus AI-enabled digital solution providing personalised pre and rehabilitation coaching and supportive care for cancer and surgery. Alvie's technology combines data profiling, risk-stratification and tailored prescriptions of health and well-being with curated educational content, targeted behaviour change coaching and expert support through chat messaging and virtual consultations.
C the Signs™ is a validated AI cancer prediction platform, which can identify patients at risk of cancer at the earliest and most curable stage of the disease. Used by healthcare professionals, C the Signs can identify which tumor type a patient is at risk of and recommend the most appropriate next step in less than 30 seconds. The platform has detected over 10,000 patients with cancer, with over 50 different types of cancer diagnosed, and with a sensitivity of >98% for cancer.
At PEP Health, We believe all patients deserve the best care possible. Our cutting-edge machine-learning technology enables healthcare organisations, regulators, and insurers the real-time, actionable insights they need to have a direct and dramatic impact on patient experiences.
PreciousMD improves the lives of lung-cancer and other lung-related illnesses patients worldwide by enabling imaging-based diagnostics needed for personalized treatment pathways.
Ufonia is an autonomous telemedicine company, we use large language models and voice AI to increase the capacity of clinical professionals.
My mhealth offers digital therapeutics for a range of long-term conditions- COPD, Asthma, Diabetes and Heart Disease. Our product has been successfully deployed in the UK and India, with >100,000 users registered to date. Our solutions empower patients to self-manage their conditions, resulting in dramatic improvements in outcomes, as evidenced through multiple clinical trials and real-world evaluations.
At Surgery Hero, we offer a clinically backed solution that ensures whole-human support before and after surgery. We help health systems, employers and health plans cut costs without sacrificing quality of care.
Panakeia's software platform enables extremely rapid multi-omics profiling in minutes directly from routinely used tissue images without needing wet lab assays.
QV Bioelectronics are striving to deliver longer, better quality lives for brain tumour patients. Using their first-of-its-kind implantable electric field therapy device, GRACE, QV will provide effective, focal & continuous treatment without impacting patient quality of life.
52 North is a med-tech company focused on improving health outcomes and health equity by reinventing care pathways. The NeutroCheck® solution is a finger-prick blood test and digital platform built to significantly improve safety and quality of life for cancer patients, by helping to identify at-home those patients who are at risk of the most fatal side-effect of chemotherapy: neutropenic sepsis.
Somnus is fulfilling an unmet need in global healthcare by developing real-time, point of care blood propofol monitoring. Its products will improve the care of sedated and anaesthetised patients, save money for hospitals, and facilitate a major reduction in greenhouse gas emissions.
ScubaTx is a breakthrough organ transplant preservation company established to solve the global unmet need for cost-efficient and longer-duration organ preservation technology. ScubaTx has developed a simple, small and affordable device which uses Persufflation to extend the preservation of organs.
IBEX is on a mission to help people live active, healthy and productive lives by increasing their access to early diagnosis of osteoporosis. The IBEX BH software as medical device delvers routine, automated assessment of fracture risk from routine radiology for earlier detection and more equitable treatment of osteoporosis.
NuVision produces products derived from donated human amniotic membrane that are used in ophthalmology to help patients with chronic, traumatic and post-surgical wounds of the eye to be treated earlier and recover more fully and more quickly. The company’s products are also used in the management of dry eye disease, a debilitating conditions that affects around 17m people in the USA.
Calon Cardio-Technology is on a mission to improve quality of life for patients with Left Ventricular Assist devices (LVAD) and reduce the common post operative complications associated with these implantable heart pumps. We plan to do this by introducing a completely wireless heart pump system and augment patient follow-up with built-in remote monitoring capabilities.

Tatiana Fofanova, co-founder and CEO of Koda, joined the Houston Innovators Podcast to discuss her company's growth. Image via LinkedIn

Houston digital health startup sees rapid expansion, grows team

HOUSTON INNOVATORS PODCAST EPISODE 155

It's Tatiana Fofanova's goal to have her company's digital health platform active in all 50 states by the end of the first quarter of 2023. She's already halfway there.

Fofanova founded Koda Health, a B2B Enterprise SaaS solution that guides patients through the process of proactive healthcare planning and document authentication, in early 2020 with her co-founders Dr. Desh Mohan, who serves as chief medical officer, and Katelin Cherry, the company's CTO. The trio connected in the Texas Medical Center's Biodesign Fellowship program and observed how advanced care planning was something that wasn't on the radar for most patients.

The tech platform allows for patients and their providers to get on the same page for their care. Fofanova describes the platform as similar to TurboTax — users answer a series of questions and the program provides a care plan then shared with the patient's doctors. This greatly simplifies — and democratizes — the process for patients and providers both.

"The standard of care for advanced care planning has traditionally been left to patients to do on their own — with estate planning attorney or through a direct-to-consumer solution," Fofanova says on this week's episode of the Houston Innovators Podcast.

But when the pandemic hit, not only did patients have a harder time accessing these services, but it also further exposed the gap between the people who traditionally could afford advanced care planning and those who could not. Koda Health targets value-based care organizations, who then onboard the platform for their patients to use for free. Fofanova says it's in these providers' best interest to have these plans established.

"For the customers we were serving — the value-based care organizations — it was there priority as well to bring those services to those populations," Fofanova says. "They save money when they deliver the right care. When they don't know the right care to deliver, everything escalates."

Within a few months of launch, Koda Health was invited to Techstars, received NSF funding, and started its first paid pilot. The pandemic was almost like a firecracker for her business, she says.

Koda Health is having another period of rapid growth. Following a $3.5 million seed funding round earlier this year, the company is developing out its product across the country, which poses several challenges for Koda.

"Regulations for medical power of attorney, advance directives, do not resuscitate orders — things like that — vary from state to state," Fofanova says. "Some states are fairly simple, but others are incredibly complicated. We've been working with a law firm to make our product legally compliant in every state, and that has required an entire rebuild of our fundamental engine in order to toggle on or off all of these requirements."

Recently launching its Spanish beta platform, Koda is now compliant in 25 states with new contracts in most of those areas already. She now has 12 full-time employees working in both Houston and remotely. This year, Koda has about 5,000 patients on its platform. Next year, based on growth projections, Fofanova says that number will grow to 100,000 before hitting 500,000 patients in 2024.

She shares more details about this growth and the future of Koda Health on the podcast. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

DECISIO has fresh funding and a new board member. Photo via decisiohealth.com

Houston health tech company raises $18.5M, appoints new leadership

fresh funding

A Houston-based digital health startup has officially closed its latest funding round and has a new member to its leadership to support the company's next phase.

DECISIO has appointed Major General Elder Granger to the company's board of directors. Dr. Granger is currently president and CEO of The 5Ps LLC, a healthcare, education, and leadership consulting organization.

"Dr. Granger joining our board provides enormous value and validation for our company moving forward," says Dr. John Holcomb, co-CEO and co-founder of DECISIO, says in a news release. "His expertise and leadership in the healthcare industry is a welcome addition to our esteemed group of Board of Directors."

Dr. Granger previously served as the deputy director of TRICARE Management Activity, a Department of Defense field activity responsible for operating the Military Health System as a fully integrated healthcare system providing care for 9.2 million beneficiaries worldwide. He also serves on the board of directors for Cerner Corp., Cigna Corp., and DLH Holdings Corp.

In February, the company officially closed its $18.5 million series B. DECISIO has raised $31.5 million since it was founded in 2013. The funding raised will go toward commercialization, continued product development, and operations growth.

Decisio is a virtual care monitoring software that's based on technology licensed from and developed at the University of Texas Health Science Center in Houston. Using real-time clinical surveillance with data visualization, the DECISIOInsight software can identify risk that helps clinicians make better patient care decisions virtually. In 2015, Decisio Health was approved by the Food and Drug Administration class II medical device, which made it the first FDA-cleared web-native software.

"Virtual Care is the next step beyond traditional telemedicine, which — for many years — was limited to having a teleconference or even just a phone call with a caregiver," Hancock previously told InnovationMap. "Now we can start sharing real-time clinical data with clinicians wherever they happen to be located."

DECISIO's flagship product is called InsightIQ, and earlier this month the company launched a new tool: EnvisionIQ, which provides templated real-time and customized compliance reports to improve operational efficiency.

Dr. Elder Granger previously oversaw the DoE's health care system. Photo courtesy

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston clean hydrogen startup to pilot tech with O&G co.

stay gold

Gold H2, a Houston-based producer of clean hydrogen, is teaming up with a major U.S.-based oil and gas company as the first step in launching a 12-month series of pilot projects.

The tentative agreement with the unnamed oil and gas company kicks off the availability of the startup’s Black 2 Gold microbial technology. The technology underpins the startup’s biotech process for converting crude oil into proprietary Gold Hydrogen.

The cleantech startup plans to sign up several oil and gas companies for the pilot program. Gold H2 says it’s been in discussions with companies in North America, Latin America, India, Eastern Europe and the Middle East.

The pilot program is aimed at demonstrating how Gold H2’s technology can transform old oil wells into hydrogen-generating assets. Gold H2, a spinout of Houston-based biotech company Cemvita, says the technology is capable of producing hydrogen that’s cheaper and cleaner than ever before.

“This business model will reshape the traditional oil and gas industry landscape by further accelerating the clean energy transition and creating new economic opportunities in areas that were previously dismissed as unviable,” Gold H2 says in a news release.

The start of the Black 2 Gold demonstrations follows the recent hiring of oil and gas industry veteran Prabhdeep Singh Sekhon as CEO.

“With the proliferation of AI, growth of data centers, and a national boom in industrial manufacturing underway, affordable … carbon-free energy is more paramount than ever,” says Rayyan Islam, co-founder and general partner at venture capital firm 8090 Industries, an investor in Gold H2. “We’re investing in Gold H2, as we know they’ll play a pivotal role in unleashing a new dawn for energy abundance in partnership with the oil industry.”

------

This article originally ran on EnergyCapital.

3 Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes an e-commerce startup founder, an industrial biologist, and a cellular scientist.

Omair Tariq, co-founder and CEO of Cart.com

Omair Tariq of Cart.com joins the Houston Innovators Podcast to share his confidence in Houston as the right place to scale his unicorn. Photo via Cart.com

Houston-based Cart.com, which operates a multichannel commerce platform, has secured $105 million in debt refinancing from investment manager BlackRock.

The debt refinancing follows a recent $25 million series C extension round, bringing Cart.com’s series C total to $85 million. The scaleup’s valuation now stands at $1.2 billion, making it one of the few $1 billion-plus “unicorns” in the Houston area.

Cart.com was co-founded by CEO Omair Tariq in October 2020. Read more.

Nádia Skorupa Parachin, vice president of industrial biotechnology at Cemvita

Nádia Skorupa Parachin joined Cemvita as vice president of industrial biotechnology. Photo courtesy of Cemvita

Houston-based biotech company Cemvita recently tapped two executives to help commercialize its sustainable fuel made from carbon waste.

Nádia Skorupa Parachin came aboard as vice president of industrial biotechnology, and Phil Garcia was promoted to vice president of commercialization.

Parachin most recently oversaw several projects at Boston-based biotech company Ginkjo Bioworks. She previously co-founded Brazilian biotech startup Integra Bioprocessos. Read more.

Han Xiao, associate professor of chemistry at Rice University

The funds were awarded to Han Xiao, a chemist at Rice University.

A Rice University chemist has landed a $2 million grant from the National Institute of Health for his work that aims to reprogram the genetic code and explore the role certain cells play in causing diseases like cancer and neurological disorders.

The funds were awarded to Han Xiao, the Norman Hackerman-Welch Young Investigator, associate professor of chemistry, from the NIH's Maximizing Investigators’ Research Award (MIRA) program, which supports medically focused laboratories. Xiao will use the five-year grant to advance his work on noncanonical amino acids.

“This innovative approach could revolutionize how we understand and control cellular functions,” Xiao said in the statement. Read more.

Houston chemist lands $2M NIH grant for cancer treatment research

future of cellular health

Xiao will use the five-year grant to develop noncanonical amino acids (ncAAs) with diverse properties to help build proteins, according to a statement from Rice. He and his team will then use the ncAAs to explore the vivo sensors for enzymes involved in posttranslational modifications (PTMs), which play a role in the development of cancers and neurological disorders. Additionally, the team will look to develop a way to detect these enzymes in living organisms in real-time rather than in a lab.

“This innovative approach could revolutionize how we understand and control cellular functions,” Xiao said in the statement.

According to Rice, these developments could have major implications for the way diseases are treated, specifically for epigenetic inhibitors that are used to treat cancer.

Xiao helped lead the charge to launch Rice's new Synthesis X Center this spring. The center, which was born out of informal meetings between Xio's lab and others from the Baylor College of Medicine’s Dan L Duncan Comprehensive Cancer Center at the Baylor College of Medicine, aims to improve cancer outcomes by turning fundamental research into clinical applications.

They will build upon annual retreats, in which investigators can share unpublished findings, and also plan to host a national conference, the first slated for this fall titled "Synthetic Innovations Towards a Cure for Cancer.”

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME